In This Article:
Key Points
-
GeneDx beat Wall Street's revenue and adjusted earnings expectations for the first quarter of 2025.
-
However, investors seem to have expected more from the company because of its past track record.
Shares of GeneDx Holdings (NASDAQ: WGS) were plunging 42.9%…